| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | GKAP/SAPAP interacting protein, OTTHUMP00000174437, SH3 and multiple ankyrin repeat domains 1, SH3 and multiple ankyrin repeat domains protein 1, SH3/ankyrin domain gene 1, SHAN1_HUMAN, SHANK 1, Shank1, Shank1a, Somatostatin receptor interacting protein, Somatostatin receptor-interacting protein, SPANK 1, SPANK1, SSTR interacting protein, SSTR-interacting protein, SSTRIP, Synamon |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Fusion protein amino acids 469-691 (SH3/PDZ domains) of rat Shank1 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
SHANK1 is a postsynaptic density (PSD) scaffolding protein that integrates neurotransmitter receptors and signaling molecules into the cortical cytoskeleton. It plays a key role in synaptic organization, plasticity, and signal transduction at excitatory synapses.
SHANK1 recruits proteins such as betaPIX and PAK to dendritic spines, regulating spine morphology and synaptic strength. It also interacts with ionotropic and metabotropic glutamate receptor complexes, contributing to synaptic signaling fidelity.
Alternative splicing of SHANK1 influences its interaction network, affecting synaptic composition during development and in the adult brain. Altered SHANK1 expression or function has been linked to cognitive deficits and neuropsychiatric conditions, highlighting its relevance in neurodegenerative disease mechanisms.
1 µg/ml of SMC-329 was sufficient for detection of Shank1 in 10 µg of rat brain lysate by colorimetric immunoblot analysis using Goat anti-mouse IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-329D — Size: 100 ug: SHANK1 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D, RRID: AB_2187578)
- SMC-329D-A390 — Size: 100 ug: SHANK1 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-A390, RRID: AB_2700465)
- SMC-329D-A488 — Size: 100 ug: SHANK1 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-A488, RRID: AB_2700466)
- SMC-329D-A594 — Size: 100 ug: SHANK1 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-A594, RRID: AB_2700468)
- SMC-329D-APC — Size: 100 ug: SHANK1 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-APC, RRID: AB_2700474)
- SMC-329D-BI — Size: 100 ug: SHANK1 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-BI, RRID: AB_2700475)
- SMC-329D-FITC — Size: 100 ug: SHANK1 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-FITC, RRID: AB_2700476)
- SMC-329D-HRP — Size: 100 ug: SHANK1 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-HRP, RRID: AB_2700477)
- SMC-329D-PCP — Size: 100 ug: SHANK1 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-PCP, RRID: AB_2700479)
- SMC-329D-RPE — Size: 100 ug: SHANK1 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329D-RPE, RRID: AB_2700480)
- SMC-329S — Size: 12 ug: SHANK1 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-329S, RRID: AB_2187578)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Kim J.H., et al. (2009) Exp Mol Med. 41(4): 236-242.
3. Gong Y., et al. (2009) Brain Res. 1292: 191-198.